Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants: ValEAR Trial

NCT03107871 is registered in ClinicalTrials.gov with Albert Park as lead sponsor.

NCT NCT03107871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03107871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants: ValEAR Trial
Lead sponsor
Albert Park
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2018
Completion date
August 31, 2022
Enrollment
10 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

cmv, cmv congenital, congenital cmv, sensorineural hearing loss, snhl